SCHEMBL7137288

SCHEMBL7137288

NC(=O)Oc1cn(Cc2c(F)cccc2F)nn1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA5A P35218 1/20 0.65
CYP2C19 P33261 1/20 0.44
KLKB1 P03952 2/20 0.43
ALDH1A1 P00352 4/20 0.43
LMNA P02545 2/20 0.43
KDM1A O60341 1/20 0.41
KDM4E B2RXH2 2/20 0.36
PRSS12 P56730 1/20 0.35
STIM1 Q13586 1/20 0.35
ORAI1 Q96D31 1/20 0.35
HDAC1 Q13547 1/20 0.35
EGFR P00533 1/20 0.34
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
FFAR1 O14842 1/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9858277 0.88 CA5A (0.59) CA5ACYP2C19KLKB1ALDH1A1LMNA
SCHEMBL27949718 0.86 CA5A (0.58) CA5ACYP2C19KLKB1ALDH1A1LMNA
SCHEMBL9858012 0.80 CYP2C19 (0.56) CA5ACYP2C19ALDH1A1LMNAKDM4E
Rufinamide SCHEMBL230448 0.79 CA5A (1.00) CA5ACYP2C19KLKB1ALDH1A1LMNA
Rufinamide SCHEMBL20769779 0.79 CA5A (1.00) CA5ACYP2C19KLKB1ALDH1A1LMNA
Rufinamide SCHEMBL17372728 0.78 CA5A (0.97) CA5ACYP2C19KLKB1ALDH1A1LMNA
SCHEMBL28478027 0.76 CA5A (0.58) CA5ACYP2C19KLKB1ALDH1A1LMNA
SCHEMBL8151152 0.76 CA5A (0.73) CA5ACYP2C19KLKB1ALDH1A1LMNA
SCHEMBL11131522 0.75 GPR55 (0.50) ALDH1A1SMN1; SMN2
SCHEMBL460913 0.74 CA5A (0.76) CA5ACYP2C19KLKB1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1729729-B1 PHARMACEUTICAL COMPOSITIONS NOVARTIS AG (CH) 2014-04-23 EP claimed
EP-0994864-B1 CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTIC NOVARTIS PHARMA GMBH (AT) 2003-04-16 EP disclosed
EP-0994863-B1 CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTIC NOVARTIS AG (CH) 2003-02-19 EP disclosed
EP-0994863-A1 CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTIC Novartis AG (CH) 2000-04-26 EP disclosed
EP-0994864-A1 CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTIC Novartis-Erfindungen Verwaltungsgesellschaft m.b.H. (AT) 2000-04-26 EP disclosed